Around 20% of breast cancers are associated with amplification or overexpression of human
epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the …

Background Overall survival is the optimal marker of treatment efficacy in randomized
clinical trials (RCTs) but can take considerable time to mature. Progression-free survival …

Introduction: This pilot study aimed to investigate the effects of using an app-based certified
medical product named PINK! on breast cancer patients and survivors. The objectives were …

Background: The overall landscape of health-related quality of life (HRQoL) has not been
thoroughly investigated in adolescents and young adults (AYAs) with cancer. Data are also …

The negative impact of unmanaged psychological distress on quality of life and outcome in
breast cancer survivors has been demonstrated. Fortunately, studies indicate that distress …

Background Trastuzumab has had a major impact on the treatment of human epidermal
growth factor receptor 2 (HER2)-positive breast cancer (BC). Anti-HER2 biosimilars such as …

Purpose Patient-reported outcomes (PROs) have been widely used to measure breast
cancer (BC) treatment outcomes. However, evidence is still limited on using routinely PROs …

The ability to predict survival in cancer is clinically important because the finding can help
patients and physicians make optimal treatment decisions. Artificial intelligence in the …

Introducción: La expresión de HER2 equivoco en cáncer de mama tiene impacto negativo
en morbimortalidad. Objetivos: Establecer la caracterización de pacientes con cáncer de …